ABL Bio (Korea) Today
| 298380 Stock | KRW 27,050 600.00 2.17% |
Performance0 of 100
| Odds Of DistressLess than 37
|
ABL Bio is trading at 27050.00 as of the 22nd of November 2024, a 2.17 percent decrease since the beginning of the trading day. The stock's open price was 27650.0. ABL Bio has about a 37 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for ABL Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of September 2024 and ending today, the 22nd of November 2024. Click here to learn more.
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio is traded on Korean Securities Dealers Automated Quotations in South Korea.. The company has 45.3 M outstanding shares. More on ABL Bio
Moving together with ABL Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
ABL Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ABL Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ABL Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
ABL Bio (298380) is traded on KOSDAQ in Korea and employs 7 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 958.17 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ABL Bio's market, we take the total number of its shares issued and multiply it by ABL Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ABL Bio operates under Healthcare sector and is part of Biotechnology industry. The entity has 45.3 M outstanding shares.
ABL Bio has accumulated about 21.59 B in cash with (40.61 B) of positive cash flow from operations.
Check ABL Bio Probability Of Bankruptcy
Ownership AllocationABL Bio holds a total of 45.3 Million outstanding shares. ABL Bio retains considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check ABL Ownership Details
ABL Bio Risk Profiles
Although ABL Bio's alpha and beta are two of the key measurements used to evaluate ABL Bio's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.49 | |||
| Standard Deviation | 4.48 | |||
| Variance | 20.11 | |||
| Risk Adjusted Performance | 0.0066 |
ABL Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in ABL Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
ABL Bio Corporate Management
Elected by the shareholders, the ABL Bio's board of directors comprises two types of representatives: ABL Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABL. The board's role is to monitor ABL Bio's management team and ensure that shareholders' interests are well served. ABL Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABL Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jung Kim | MD COO | Profile | |
| Jaecheon Lee | MD CFO | Profile | |
| Jae Jung | MD Discovery | Profile | |
| Jong Kim | MD Devel | Profile | |
| Sang Lee | Founder CEO | Profile | |
| You WeonKyoo | Head MD | Profile | |
| Jong Won | Head Devel | Profile |
Other Information on Investing in ABL Stock
ABL Bio financial ratios help investors to determine whether ABL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABL with respect to the benefits of owning ABL Bio security.